Cue Biopharma, Inc. Depreciation
Cue Biopharma, Inc. (CUE) reported Depreciation of $33.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-14
- Cue Biopharma, Inc. depreciation for the quarter ending 2026-06-30 was $33.00K, a 65.98% decline year-over-year.
- Cue Biopharma, Inc. depreciation for the quarter ending 2026-03-31 was $74.00K, a 23.71% decline year-over-year.
- Cue Biopharma, Inc. depreciation for the quarter ending 2025-12-31 was $65.00K, a 31.58% decline year-over-year.
- Cue Biopharma, Inc. depreciation for the quarter ending 2025-09-30 was $76.00K, a 21.65% decline year-over-year.
- Cue Biopharma, Inc. depreciation for fiscal 2025 was $336.00K, a 12.73% decline from fiscal 2024.
- Cue Biopharma, Inc. depreciation for fiscal 2024 was $385.00K, a 29.36% decline from fiscal 2023.
- Cue Biopharma, Inc. depreciation for fiscal 2023 was $545.00K, a 34.42% decline from fiscal 2022.
- Cue Biopharma, Inc. depreciation for fiscal 2022 was $831.00K, a 8.59% decline from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 6 month as first filed | Depreciation 9 month | Depreciation 9 month as first filed | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $33.00K 10-Q · filed 2026-08-14 | $107.00K 10-Q · filed 2026-08-14 | $172.00K derived: sum of 3 quarters · filed 2026-08-14 | $248.00K derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | $74.00K 10-Q · filed 2026-05-14 | $139.00K derived: sum of 2 quarters · filed 2026-05-14 | $215.00K derived: sum of 3 quarters · filed 2026-05-14 | $312.00K derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-12-31 | $65.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $141.00K derived: sum of 2 quarters · filed 2026-03-16 | $238.00K derived: sum of 3 quarters · filed 2026-08-14 | $336.00K 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | $76.00K 10-Q · filed 2025-11-12 | $173.00K derived: sum of 2 quarters · filed 2026-08-14 | $271.00K 10-Q · filed 2025-11-12 | $365.00K derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | $97.00K 10-Q · filed 2026-08-14 | $194.00K 10-Q · filed 2026-08-14 | $289.00K derived: sum of 3 quarters · filed 2026-08-14 | $386.00K derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-03-31 | $97.00K 10-Q · filed 2026-05-14 | $192.00K derived: sum of 2 quarters · filed 2026-05-14 | $289.00K derived: sum of 3 quarters · filed 2026-05-14 | $389.00K derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $192.00K derived: sum of 2 quarters · filed 2026-03-16 | $292.00K derived: sum of 3 quarters · filed 2026-03-16 | $385.00K 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | $97.00K 10-Q · filed 2025-11-12 | $100.00K 10-Q · filed 2024-11-14 | $197.00K derived: sum of 2 quarters · filed 2025-11-12 | $290.00K 10-Q · filed 2025-11-12 | $300.00K 10-Q · filed 2024-11-14 | $438.00K derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $100.00K 10-Q · filed 2025-08-12 | $198.00K 10-Q · filed 2025-08-12 | $200.00K 10-Q · filed 2024-08-14 | $341.00K derived: sum of 3 quarters · filed 2025-08-12 | $441.00K derived: sum of 4 quarters · filed 2025-08-12 | |||
| 2024-03-31 | $96.00K 10-Q · filed 2025-05-12 | $241.00K derived: sum of 2 quarters · filed 2025-05-12 | $341.00K derived: sum of 3 quarters · filed 2025-05-12 | $441.00K derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | $145.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $245.00K derived: sum of 2 quarters · filed 2025-03-31 | $345.00K derived: sum of 3 quarters · filed 2025-03-31 | $545.00K 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $100.00K 10-Q · filed 2024-11-14 | $128.00K 10-Q · filed 2023-11-03 | $200.00K derived: sum of 2 quarters · filed 2024-11-14 | $400.00K 10-Q · filed 2024-11-14 | $434.00K 10-Q · filed 2023-11-03 | $575.00K derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $100.00K 10-Q · filed 2024-08-14 | $132.00K 10-Q · filed 2023-08-08 | $300.00K 10-Q · filed 2024-08-14 | $307.00K 10-Q · filed 2023-08-08 | $475.00K derived: sum of 3 quarters · filed 2024-08-14 | $673.00K derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $174.00K 10-Q · filed 2024-05-09 | $375.00K derived: sum of 2 quarters · filed 2024-05-09 | $573.00K derived: sum of 3 quarters · filed 2024-05-09 | $785.00K derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $201.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $399.00K derived: sum of 2 quarters · filed 2024-03-28 | $611.00K derived: sum of 3 quarters · filed 2024-03-28 | $831.00K 10-K · filed 2024-03-28 | $830.58K 10-K · filed 2023-03-21 | |||
| 2022-09-30 | $198.00K 10-Q · filed 2023-11-03 | $410.00K derived: sum of 2 quarters · filed 2023-11-03 | $630.00K 10-Q · filed 2023-11-03 | $857.11K derived: sum of 4 quarters · filed 2023-11-03 | ||||
| 2022-06-30 | $212.00K 10-Q · filed 2023-08-08 | $432.00K 10-Q · filed 2023-08-08 | $659.11K derived: sum of 3 quarters · filed 2023-08-08 | $891.11K derived: sum of 4 quarters · filed 2023-08-08 | ||||
| 2022-03-31 | $220.00K 10-Q · filed 2023-05-09 | $447.11K derived: sum of 2 quarters · filed 2023-05-09 | $679.11K derived: sum of 3 quarters · filed 2023-05-09 | $910.11K derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | $227.11K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $459.11K derived: sum of 2 quarters · filed 2023-03-21 | $690.11K derived: sum of 3 quarters · filed 2023-03-21 | $909.11K 10-K · filed 2023-03-21 | ||||
| 2021-09-30 | $232.00K 10-Q · filed 2022-11-14 | $463.00K derived: sum of 2 quarters · filed 2022-11-14 | $682.00K 10-Q · filed 2022-11-14 | $865.53K derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $231.00K 10-Q · filed 2022-08-04 | $449.00K 10-Q · filed 2022-08-04 | $633.53K derived: sum of 3 quarters · filed 2022-08-04 | $832.53K derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | $218.00K 10-Q · filed 2022-05-10 | $402.53K derived: sum of 2 quarters · filed 2022-05-10 | $601.53K derived: sum of 3 quarters · filed 2022-05-10 | $803.53K derived: sum of 4 quarters · filed 2022-05-10 | ||||
| 2020-12-31 | $184.53K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $383.53K derived: sum of 2 quarters · filed 2022-03-16 | $585.53K derived: sum of 3 quarters · filed 2022-03-16 | $780.53K 10-K · filed 2022-03-16 | ||||
| 2020-09-30 | $199.00K 10-Q · filed 2021-11-09 | $401.00K derived: sum of 2 quarters · filed 2021-11-09 | $596.00K 10-Q · filed 2021-11-09 | $789.11K derived: sum of 4 quarters · filed 2021-11-09 | ||||
| 2020-06-30 | $202.00K 10-Q · filed 2021-08-09 | $396.00K 10-Q · filed 2021-08-09 | $590.11K derived: sum of 3 quarters · filed 2021-08-09 | $784.11K derived: sum of 4 quarters · filed 2021-08-09 | ||||
| 2020-03-31 | $194.00K 10-Q · filed 2021-05-10 | $388.11K derived: sum of 2 quarters · filed 2021-05-10 | $582.11K derived: sum of 3 quarters · filed 2021-05-10 | $787.11K derived: sum of 4 quarters · filed 2021-05-10 | ||||
| 2019-12-31 | $194.11K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $388.11K derived: sum of 2 quarters · filed 2021-03-09 | $593.11K derived: sum of 3 quarters · filed 2021-03-09 | $799.11K 10-K · filed 2021-03-09 | ||||
| 2019-09-30 | $194.00K 10-Q · filed 2020-11-09 | $399.00K derived: sum of 2 quarters · filed 2020-11-09 | $605.00K 10-Q · filed 2020-11-09 | $808.01K derived: sum of 4 quarters · filed 2020-11-09 | ||||
| 2019-06-30 | $205.00K 10-Q · filed 2020-08-07 | $410.00K 10-Q · filed 2020-08-07 | $614.01K derived: sum of 3 quarters · filed 2020-08-07 | $809.01K derived: sum of 4 quarters · filed 2020-08-07 | ||||
| 2019-03-31 | $205.00K 10-Q · filed 2020-05-07 | $409.01K derived: sum of 2 quarters · filed 2020-05-07 | $604.01K derived: sum of 3 quarters · filed 2020-05-07 | $799.01K derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $204.01K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $399.01K derived: sum of 2 quarters · filed 2020-03-12 | $594.01K derived: sum of 3 quarters · filed 2020-03-12 | $760.01K 10-K · filed 2020-03-12 | ||||
| 2018-09-30 | $195.00K 10-Q · filed 2019-11-07 | $390.00K derived: sum of 2 quarters · filed 2019-11-07 | $556.00K 10-Q · filed 2019-11-07 | $683.57K derived: sum of 4 quarters · filed 2019-11-07 | ||||
| 2018-06-30 | $195.00K 10-Q · filed 2019-08-08 | $362.00K 10-Q · filed 2019-08-08 | $488.57K derived: sum of 3 quarters · filed 2019-08-08 | $612.57K derived: sum of 4 quarters · filed 2019-08-08 | ||||
| 2018-03-31 | $167.00K 10-Q · filed 2019-05-08 | $293.57K derived: sum of 2 quarters · filed 2019-05-08 | $417.57K derived: sum of 3 quarters · filed 2019-05-08 | $519.57K derived: sum of 4 quarters · filed 2019-05-08 | ||||
| 2017-12-31 | $126.57K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $250.57K derived: sum of 2 quarters · filed 2019-03-14 | $352.57K derived: sum of 3 quarters · filed 2019-03-14 | $419.57K 10-K · filed 2019-03-14 | ||||
| 2017-09-30 | $124.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $226.00K derived: sum of 2 quarters · filed 2018-11-13 | $293.00K 10-Q · filed 2018-11-13 | |||||
| 2017-06-30 | $102.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $169.00K 10-Q · filed 2018-08-13 | ||||||
| 2017-03-31 | $67.00K 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |